Viral Vector and Plasmid DNA Manufacturing Market Size, Share, and Outlook, H2-2025 Report- By Type (Viral Vectors, Plasmid DNA), By Products and Services (Product, Services), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application
Description
Viral Vector and Plasmid DNA Manufacturing Market Outlook
The global Viral Vector and Plasmid DNA Manufacturing Market Size is valued at $8.3 Billion in 2025 and is forecast to reach $27.4 Billion in 2032 at a CAGR of 18.6%.
The Viral Vector and Plasmid DNA Manufacturing Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Viral Vector and Plasmid DNA Manufacturing Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Viral Vectors, Plasmid DNA), By Products and Services (Product, Services), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application (Cell and Gene Therapy, Vaccine Development, Research), By Disease (Cancer, Generic Disorders, Infectious Diseases, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Viral Vector and Plasmid DNA Manufacturing Market Insights, 2025
The market for viral vector and plasmid DNA manufacturing is expanding due to the rise of gene therapies, mRNA vaccines, and viral-based therapeutics. Recent developments include high-yield plasmid production platforms, scalable viral vector manufacturing processes, and closed-system bioreactors. Companies are focusing on enhancing purity, reducing production timelines, and complying with cGMP standards. Growth is fueled by increasing demand for personalized medicine, gene editing therapies, and clinical trials. Research emphasizes process optimization, automation, and analytical methods for quality control. Emerging trends include modular manufacturing facilities, single-use systems, and AI-assisted production monitoring. Regulatory approvals and standardization frameworks are facilitating global adoption. Overall, the market prioritizes efficiency, scalability, and regulatory-compliant production of viral vectors and plasmid DNA.
Five Trends Shaping the Global Viral Vector and Plasmid DNA Manufacturing Market in 2025 and Beyond
The global Viral Vector and Plasmid DNA Manufacturing Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Viral Vector and Plasmid DNA Manufacturing Industry?
The Viral Vector and Plasmid DNA Manufacturing Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Viral Vector and Plasmid DNA Manufacturing Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Viral Vector and Plasmid DNA Manufacturing Market Segment Insights
The Viral Vector and Plasmid DNA Manufacturing Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Viral Vectors, Plasmid DNA), By Products and Services (Product, Services), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application (Cell and Gene Therapy, Vaccine Development, Research), By Disease (Cancer, Generic Disorders, Infectious Diseases, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Viral Vector and Plasmid DNA Manufacturing Industry Value Chain
The chapter identifies potential companies and their operations across the global Viral Vector and Plasmid DNA Manufacturing Industry ecosystem. It assists decision-makers in evaluating global Viral Vector and Plasmid DNA Manufacturing Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Viral Vector and Plasmid DNA Manufacturing Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Viral Vector and Plasmid DNA Manufacturing Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Viral Vector and Plasmid DNA Manufacturing Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Viral Vector and Plasmid DNA Manufacturing Market.
Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Viral Vector and Plasmid DNA Manufacturing Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Viral Vector and Plasmid DNA Manufacturing Industry competitiveness. The report analyses the key Viral Vector and Plasmid DNA Manufacturing Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Viral Vector and Plasmid DNA Manufacturing Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Viral Vector and Plasmid DNA Manufacturing Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Viral Vector and Plasmid DNA Manufacturing Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Viral Vector and Plasmid DNA Manufacturing Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Viral Vector and Plasmid DNA Manufacturing Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Batavia Biosciences B.V., Bluebird Bio Inc, Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, Danaher Corp, FUJIFILM Corp, GenScript Biotech Corp, Kaneka Eurogentec S.A., Lonza Group AG, Merck KGaA, Novartis AG, Oxford Biomedica PLC, PlasmidFactory GmbH & Co. KG, Precision Biosciences, Sartorius AG, SIRONA BIOCHEM Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, VGXI Inc, Waisman Biomanufacturing, WuXi AppTec Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Viral Vector and Plasmid DNA Manufacturing Market Scope
Leading Segments
By Type
Viral VectorsRetroviruses Adenoviruses Adeno-associated viruses (AAVs) Lentiviruses Others
Plasmid DNA
By Products and Services
Product
Services
By Workflow
Upstream Manufacturing
Downstream Manufacturing
By Application
Cell and Gene Therapy
Vaccine Development
Research
By Disease
Cancer
Generic Disorders
Infectious Diseases
Others
By End-User
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others
Leading Companies
Batavia Biosciences B.V.
Bluebird Bio Inc
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
Danaher Corp
FUJIFILM Corp
GenScript Biotech Corp
Kaneka Eurogentec S.A.
Lonza Group AG
Merck KGaA
Novartis AG
Oxford Biomedica PLC
PlasmidFactory GmbH & Co. KG
Precision Biosciences
Sartorius AG
SIRONA BIOCHEM Corp
Takara Bio Inc
Thermo Fisher Scientific Inc
VGXI Inc
Waisman Biomanufacturing
WuXi AppTec Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Viral Vector and Plasmid DNA Manufacturing Market Size is valued at $8.3 Billion in 2025 and is forecast to reach $27.4 Billion in 2032 at a CAGR of 18.6%.
The Viral Vector and Plasmid DNA Manufacturing Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Viral Vector and Plasmid DNA Manufacturing Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Viral Vectors, Plasmid DNA), By Products and Services (Product, Services), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application (Cell and Gene Therapy, Vaccine Development, Research), By Disease (Cancer, Generic Disorders, Infectious Diseases, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Viral Vector and Plasmid DNA Manufacturing Market Insights, 2025
The market for viral vector and plasmid DNA manufacturing is expanding due to the rise of gene therapies, mRNA vaccines, and viral-based therapeutics. Recent developments include high-yield plasmid production platforms, scalable viral vector manufacturing processes, and closed-system bioreactors. Companies are focusing on enhancing purity, reducing production timelines, and complying with cGMP standards. Growth is fueled by increasing demand for personalized medicine, gene editing therapies, and clinical trials. Research emphasizes process optimization, automation, and analytical methods for quality control. Emerging trends include modular manufacturing facilities, single-use systems, and AI-assisted production monitoring. Regulatory approvals and standardization frameworks are facilitating global adoption. Overall, the market prioritizes efficiency, scalability, and regulatory-compliant production of viral vectors and plasmid DNA.
Five Trends Shaping the Global Viral Vector and Plasmid DNA Manufacturing Market in 2025 and Beyond
The global Viral Vector and Plasmid DNA Manufacturing Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Viral Vector and Plasmid DNA Manufacturing Industry?
The Viral Vector and Plasmid DNA Manufacturing Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Viral Vector and Plasmid DNA Manufacturing Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Viral Vector and Plasmid DNA Manufacturing Market Segment Insights
The Viral Vector and Plasmid DNA Manufacturing Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Viral Vectors, Plasmid DNA), By Products and Services (Product, Services), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application (Cell and Gene Therapy, Vaccine Development, Research), By Disease (Cancer, Generic Disorders, Infectious Diseases, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Viral Vector and Plasmid DNA Manufacturing Industry Value Chain
The chapter identifies potential companies and their operations across the global Viral Vector and Plasmid DNA Manufacturing Industry ecosystem. It assists decision-makers in evaluating global Viral Vector and Plasmid DNA Manufacturing Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Viral Vector and Plasmid DNA Manufacturing Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Viral Vector and Plasmid DNA Manufacturing Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Viral Vector and Plasmid DNA Manufacturing Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Viral Vector and Plasmid DNA Manufacturing Market.
Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Viral Vector and Plasmid DNA Manufacturing Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Viral Vector and Plasmid DNA Manufacturing Industry competitiveness. The report analyses the key Viral Vector and Plasmid DNA Manufacturing Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Viral Vector and Plasmid DNA Manufacturing Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Viral Vector and Plasmid DNA Manufacturing Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Viral Vector and Plasmid DNA Manufacturing Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Viral Vector and Plasmid DNA Manufacturing Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Viral Vector and Plasmid DNA Manufacturing Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Batavia Biosciences B.V., Bluebird Bio Inc, Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, Danaher Corp, FUJIFILM Corp, GenScript Biotech Corp, Kaneka Eurogentec S.A., Lonza Group AG, Merck KGaA, Novartis AG, Oxford Biomedica PLC, PlasmidFactory GmbH & Co. KG, Precision Biosciences, Sartorius AG, SIRONA BIOCHEM Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, VGXI Inc, Waisman Biomanufacturing, WuXi AppTec Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Viral Vector and Plasmid DNA Manufacturing Market Scope
Leading Segments
By Type
Viral Vectors
Plasmid DNA
By Products and Services
Product
Services
By Workflow
Upstream Manufacturing
Downstream Manufacturing
By Application
Cell and Gene Therapy
Vaccine Development
Research
By Disease
Cancer
Generic Disorders
Infectious Diseases
Others
By End-User
Pharmaceutical and Biopharmaceutical Companies
Academics and Research Institutes
Others
Leading Companies
Batavia Biosciences B.V.
Bluebird Bio Inc
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
Danaher Corp
FUJIFILM Corp
GenScript Biotech Corp
Kaneka Eurogentec S.A.
Lonza Group AG
Merck KGaA
Novartis AG
Oxford Biomedica PLC
PlasmidFactory GmbH & Co. KG
Precision Biosciences
Sartorius AG
SIRONA BIOCHEM Corp
Takara Bio Inc
Thermo Fisher Scientific Inc
VGXI Inc
Waisman Biomanufacturing
WuXi AppTec Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
199 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Viral Vector and Plasmid DNA Manufacturing Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Viral Vector and Plasmid DNA Manufacturing Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Viral Vector and Plasmid DNA Manufacturing Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Viral Vector and Plasmid DNA Manufacturing Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Viral Vector and Plasmid DNA Manufacturing Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Type
- Viral Vectors
- -Retroviruses
- -Adenoviruses
- -Adeno-associated viruses (AAVs)
- -Lentiviruses
- -Others
- Plasmid DNA
- By Products and Services
- Product
- Services
- By Workflow
- Upstream Manufacturing
- Downstream Manufacturing
- By Application
- Cell and Gene Therapy
- Vaccine Development
- Research
- By Disease
- Cancer
- Generic Disorders
- Infectious Diseases
- Others
- By End-User
- Pharmaceutical and Biopharmaceutical Companies
- Academics and Research Institutes
- Others
- 6. Global Viral Vector and Plasmid DNA Manufacturing Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Viral Vector and Plasmid DNA Manufacturing Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Viral Vector and Plasmid DNA Manufacturing Market Trends and Growth Opportunities
- 6.2.1 North America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Type
- 6.2.2 North America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Application
- 6.3 North America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Country
- 6.3.1 The US Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 6.3.2 Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 6.3.3 Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7. Europe Viral Vector and Plasmid DNA Manufacturing Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Viral Vector and Plasmid DNA Manufacturing Market Trends and Growth Opportunities
- 7.2.1 Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook by Type
- 7.2.2 Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook by Application
- 7.3 Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook by Country
- 7.3.2 Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.3 France Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.4 The UK Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.5 Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.6 Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.7 Russia Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook by Type
- 8.2.2 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook by Application
- 8.3 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook by Country
- 8.3.1 China Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.2 India Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.3 Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.4 South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.5 Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.6 South East Asia Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 9. South America Viral Vector and Plasmid DNA Manufacturing Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Viral Vector and Plasmid DNA Manufacturing Market Trends and Growth Opportunities
- 9.2.1 South America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Type
- 9.2.2 South America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Application
- 9.3 South America Viral Vector and Plasmid DNA Manufacturing Market Outlook by Country
- 9.3.1 Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 9.3.2 Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10. Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook by Type
- 10.2.2 Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook by Application
- 10.3 Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook by Country
- 10.3.1 Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10.3.2 The UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10.3.4 South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10.3.5 Egypt Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- Batavia Biosciences B.V.
- Bluebird Bio Inc
- Catalent Inc
- Cell and Gene Therapy Catapult
- Charles River Laboratories International Inc
- Danaher Corp
- FUJIFILM Corp
- GenScript Biotech Corp
- Kaneka Eurogentec S.A.
- Lonza Group AG
- Merck KGaA
- Novartis AG
- Oxford Biomedica PLC
- PlasmidFactory GmbH & Co. KG
- Precision Biosciences
- Sartorius AG
- SIRONA BIOCHEM Corp
- Takara Bio Inc
- Thermo Fisher Scientific Inc
- VGXI Inc
- Waisman Biomanufacturing
- WuXi AppTec Co. Ltd
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
